<DOC>
	<DOC>NCT02157714</DOC>
	<brief_summary>This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.</brief_summary>
	<brief_title>Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Idiopathic Parkinson's disease, Hoehn and Yahr 13 Body weight range of ≥ 45kg/99 lbs to ≤ 110 kg/242 lbs Female subjects must be surgically sterile or postmenopausal or if of childbearing potential must use contraception Male subjects and their partners of childbearing potential must use contraception Significant cardiac history Abnormal MRI Significant laboratory abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>